Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 12/20 | 1.00 |
| ▸ | PDE2A | O00408 | 10/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 9/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 0.90 |
| ▸ | TSPO | P30536 | 1/20 | 0.90 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.90 |
| ▸ | DRD3 | P35462 | 1/20 | 0.90 |
| ▸ | PTGFR | P43088 | 1/20 | 0.90 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.90 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.90 |
| ▸ | PTGIR | P43119 | 1/20 | 0.90 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.90 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548354 | 1.00 | PTGDR (1.00) | PTGDRPDE2ATBXA2RPDE4ATSPO | |
| Laropiprant SCHEMBL29612617 | 0.95 | PTGDR (1.00) | PTGDRPDE2ATBXA2RPDE4ATSPO | |
| Diastereomer 2 SCHEMBL32668949 | 0.95 | PTGDR (1.00) | PTGDRPDE2ATBXA2RPDE4ATSPO | |
| Laropiprant SCHEMBL991107 | 0.95 | PTGDR (1.00) | PTGDRPDE2ATBXA2RPDE4ATSPO | |
| Diastereomer 2 SCHEMBL1044552 | 0.95 | PTGDR (1.00) | PTGDRPDE2ATBXA2RPDE4ATSPO | |
| SCHEMBL4458417 | 0.92 | PTGDR (0.86) | PTGDRPDE2ATBXA2RPDE4ATSPO | |
| SCHEMBL14472807 | 0.92 | PTGDR (0.85) | PTGDRPDE2ATBXA2RPDE4ATSPO | |
| SCHEMBL19799336 | 0.88 | PTGDR (0.86) | PTGDRPDE2ATBXA2RPDE4ATSPO | |
| SCHEMBL13344157 | 0.88 | PTGDR (0.86) | PTGDRPDE2ATBXA2RPDE4ATSPO | |
| SCHEMBL13344139 | 0.88 | PTGDR (0.86) | PTGDRPDE2ATBXA2RPDE4ATSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033028-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | BERTHELETTE CARL | 2008-02-07 | — | — | US | claimed |
| US-20060069148-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | BERTHELETTE CARL | 2006-03-30 | — | — | US | claimed |
| US-20050124680-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | MERCK CANADA INC. (CA) | 2005-06-09 | — | — | US | claimed |
| EP-1470107-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2004-10-27 | — | — | EP | claimed |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | MERCK FROSST CANADA & CO. (CA) | 2003-08-21 | — | — | US | claimed |
| WO-2003062200-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2003-07-31 | — | — | WO | claimed |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3175856-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS | The Trustees of the University of Pennsylvania (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2037967-B1 | PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR TREATING ANDROGENETIC ALOPECIA | UNIV PENNSYLVANIA (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007035478-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007027532-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1470107-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2004-10-27 | — | — | EP | disclosed |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | MERCK FROSST CANADA & CO. (CA) | 2003-08-21 | — | — | US | disclosed |
| WO-2003062200-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069148-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | PTGDR 7/4885PDE2A 463/4885TBXA2R 17/4885 |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | PTGES, PTGIR, PTGER1 | PTGDR 14/4885PDE2A 362/4885TBXA2R 25/4885 |
| US-20050124680-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | PTGDR 7/4885PDE2A 463/4885TBXA2R 17/4885 |
| US-20080033028-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | PTGDR 7/4885PDE2A 463/4885TBXA2R 17/4885 |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | AR, BPHL, PTGS2 | PTGDR 10/4885PDE2A 558/4885TBXA2R 888/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | PTGDR 509/4885PDE2A 706/4885TBXA2R 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.